

Date: April 25, 2022

|  |  |
|--|--|
| To,<br>The Manager, Listing Department,<br><b>National Stock Exchange of India Limited (NSE),</b><br>Exchange Plaza, C-1, Block-G, Bandra - Kurla Complex, Bandra (E), Mumbai-400 051. | To,<br>The Department of Corporate Service,<br><b>BSE Limited</b><br>1 <sup>st</sup> Floor, New Trading Ring,<br>Rotunda Building, Phiroze Jeejeebhoy Tower, Dalal Street, Mumbai-400 001. |
| <b>Scrip Code – LINCOLN</b>  | <b>Scrip Code – 531633</b>   |

Dear Ma'am / Sir,

**SUB: REPORTING OF INITIAL DISCLOSURE TO BE MADE BY ENTITIES IDENTIFIED AS LARGE CORPORATES.**


Pursuant to the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018 ("Circular"), we hereby confirm that the Company i.e. Lincoln Pharmaceuticals Ltd is not falling under the category of Large Corporate Entity as per the framework / applicability criteria mentioned in clause 2.2 of the said circular as on March 31, 2022.

Accordingly the initial disclosure in "Annexure A" to the said circular is not applicable to us.

Kindly take the above on record.

Thanking you.

**Yours faithfully**  
**For Lincoln Pharmaceuticals Ltd**

*N.A. Desai*  
  
**Niren A. Desai**  
**Company Secretary &**  
**Compliance Officer**